Your session is about to expire
← Back to Search
Ribociclib for Breast Cancer (MONALEESA-3 Trial)
MONALEESA-3 Trial Summary
This trial is testing a new cancer drug combo to see if it's effective and safe for people with hormone-positive, HER2-negative breast cancer who've had little to no prior treatment.
- Breast Cancer
MONALEESA-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMONALEESA-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MONALEESA-3 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
By how many people is this trial being organized?
"To make participation more accessible, this trial is running at 40 locations. If you choose to enroll, the site selection tool can help you find the centre that is closest to your home."
How many individuals are a part of this test group?
"Recruitment for this study is not currently underway. However, the clinical trial was first posted on 6/9/2015 and last edited on 11/10/2022. If you are interested in alternative studies, 2373 trials for patients with breast cancer and 185 trials for those taking Ribociclib are enrolling at this time."
Are there any volunteers needed for this research project?
"The clinicaltrials.gov website reveals that this study isn't currently looking for new participants. Although, this could change in the future as the trial was most recently updated on November 10th, 2022. Additionally, there are 2558 other trials that are actively recruiting patients."
Are there any similar studies that have been conducted with Ribociclib?
"As of right now, there are 185 ongoing clinical trials researching the use of Ribociclib. This includes 38 Phase 3 trials. Additionally, although many trials for Ribociclib are based in Shanghai, China, there are a total of 7574 locations running these sorts of tests."
Could you please list any negative side effects associated with Ribociclib?
"This medication has received a safety rating of 3. This is due to the fact that it is a Phase 3 trial, meaning that there is both efficacy data as well as multiple rounds of safety data supporting its use."
For what purpose is Ribociclib most often prescribed?
"Ribociclib is frequently used to target malignant neoplasms. Additionally, this medication can be employed to fight pik3ca gene mutation, progression, disease, and prior endocrine therapy."
Share this study with friends
Copy Link
Messenger